IN2012DN02120A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02120A
IN2012DN02120A IN2120DEN2012A IN2012DN02120A IN 2012DN02120 A IN2012DN02120 A IN 2012DN02120A IN 2120DEN2012 A IN2120DEN2012 A IN 2120DEN2012A IN 2012DN02120 A IN2012DN02120 A IN 2012DN02120A
Authority
IN
India
Prior art keywords
vip
modified
receptor
binding
vips
Prior art date
Application number
Inventor
Homayoun Sadeghi
Andrew Turner
Suzanne Dagher
Original Assignee
Phasebio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasebio Pharmaceuticals Inc filed Critical Phasebio Pharmaceuticals Inc
Publication of IN2012DN02120A publication Critical patent/IN2012DN02120A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
IN2120DEN2012 2009-08-14 2010-08-16 IN2012DN02120A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23415109P 2009-08-14 2009-08-14
PCT/US2010/045605 WO2011020091A1 (en) 2009-08-14 2010-08-16 Modified vasoactive intestinal peptides

Publications (1)

Publication Number Publication Date
IN2012DN02120A true IN2012DN02120A (en) 2015-08-21

Family

ID=43586545

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2120DEN2012 IN2012DN02120A (en) 2009-08-14 2010-08-16

Country Status (19)

Country Link
US (4) US9029505B2 (en)
EP (2) EP2464370B1 (en)
JP (3) JP5801807B2 (en)
KR (2) KR101943420B1 (en)
CN (1) CN102596217B (en)
AU (3) AU2010282250B2 (en)
BR (1) BR112012003327A2 (en)
CA (1) CA2804755C (en)
DK (2) DK2464370T3 (en)
ES (2) ES2624478T3 (en)
HU (2) HUE032703T2 (en)
IL (1) IL218116A (en)
IN (1) IN2012DN02120A (en)
MX (2) MX339031B (en)
PL (2) PL2464370T3 (en)
PT (2) PT2464370T (en)
RU (1) RU2589255C2 (en)
SG (1) SG10201407329RA (en)
WO (1) WO2011020091A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
CA2804755C (en) 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
EP2717902B1 (en) * 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
JP6169079B2 (en) * 2011-08-24 2017-07-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド Formulation of active agent for sustained release
RU2014126244A (en) * 2011-11-28 2016-01-27 Фэйзбио Фармасьютикалз, Инк. AMINO ACID MEDICINES CONTAINING INSULIN SEQUENCES
WO2014081849A1 (en) * 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
AU2015255752B2 (en) * 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
CN107206044A (en) 2014-11-21 2017-09-26 费斯生物制药公司 ELP fusion protein for controlled and sustained release
CN105753990B (en) * 2014-12-19 2018-07-03 兰州大学 A kind of fusion protein of vasoactive intestinal peptide and its preparation method and application
AU2016219513B2 (en) * 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
WO2017152399A1 (en) * 2016-03-09 2017-09-14 兰州大学 Fusion protein of vasoactive intestinal peptide and preparation method and use thereof
CN109310641A (en) 2016-05-06 2019-02-05 费斯生物制药公司 ELP fusion proteins for controlled and sustained release
CN107056922A (en) * 2016-12-24 2017-08-18 山东明鑫集团有限公司 A kind of preparation method of the PACAP polypeptide analogs with hypoglycemic effect
US11786580B2 (en) * 2018-04-23 2023-10-17 Emory University VIP and VIP agonists, nanoparticles, and uses in inflammatory T-cell mediated disease
KR102238519B1 (en) * 2018-12-28 2021-04-13 (주)메디톡스 Microorganism expressing heterologous protein, and use thereof
KR102719035B1 (en) * 2020-04-20 2024-10-18 주식회사 리비옴 Microorganism expressing vasoactive intestinal peptide, and use thereof
US20230173030A1 (en) * 2020-05-05 2023-06-08 Phasebio Pharmaceuticals, Inc. Vasoactive intestinal peptide fusion proteins for the treatment of covid-19
EP4326310A1 (en) 2021-04-20 2024-02-28 AdVita Lifescience AG Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome
CN119390812B (en) * 2024-11-08 2025-07-29 三亚市私域大健康医院有限公司 Stem cell exosome composition for treating erectile dysfunction and application thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132746A (en) * 1976-07-09 1979-01-02 University Of Alabama, Birmingham Medical & Education Foundation Synthetic elastomeric insoluble cross-linked polypentapeptide
US4187852A (en) * 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
US4500700A (en) * 1981-10-02 1985-02-19 The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
US4474851A (en) 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4589882A (en) * 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US4734400A (en) 1984-10-09 1988-03-29 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4783523A (en) * 1986-08-27 1988-11-08 Urry Dan W Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
US4870055A (en) * 1986-04-17 1989-09-26 University Of Alabama At Birmingham Segmented polypeptide bioelastomers to modulate elastic modulus
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US4898926A (en) * 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
US5641648A (en) * 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6184348B1 (en) * 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5773249A (en) * 1986-11-04 1998-06-30 Protein Polymer Technologies, Inc. High molecular weight collagen-like protein polymers
US5830713A (en) * 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5770697A (en) * 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US5496712A (en) * 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4939224A (en) 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5141924A (en) 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs
US5234907A (en) * 1989-06-30 1993-08-10 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
ATE114458T1 (en) 1990-03-27 1994-12-15 Bioelastics Res Ltd BIOELASTOMERIC DRUG DELIVERY SYSTEM.
ES2063406T3 (en) * 1990-06-26 1995-01-01 Sanwa Kagaku Kenkyusho Co PROCEDURE FOR THE PREPARATION OF VASOACTIVE INTESTINAL POLYPEPTIDE ANALOGS.
JPH07108232B2 (en) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 Method for producing peptide or protein
US5235041A (en) * 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5393602A (en) * 1991-04-19 1995-02-28 Bioelastics Research Ltd. Superabsorbent materials and uses thereof
JPH05238950A (en) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd Readily absorbable vip pharmaceutical
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
AU656230B2 (en) 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
US5681816A (en) * 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5900405A (en) * 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
CA2187322A1 (en) * 1994-04-07 1995-10-19 Israel Rubinstein Vasoactive intestinal polypeptide
US5527610A (en) * 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US5854387A (en) 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US6004782A (en) 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5972406A (en) * 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6037321A (en) * 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
US5998588A (en) 1995-09-01 1999-12-07 University Of Washington Interactive molecular conjugates
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
CN103275221B (en) * 1996-02-09 2016-08-17 艾伯维生物技术有限公司 People's antibody in conjunction with human TNF alpha
WO1997029126A1 (en) 1996-02-09 1997-08-14 F. Hoffmann-La Roche Ag Synthesis of vip analog
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5816259A (en) * 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1056413A4 (en) * 1998-02-27 2003-08-20 Bioelastics Res Ltd Injectable implants for tissue augmentation and restoration
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2776520B1 (en) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PEPTIDES AND THEIR PREPARATION PROCESS
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US20020151458A1 (en) * 1998-04-17 2002-10-17 Perez Gomariz Rosa Maria Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
ES2138561B1 (en) * 1998-04-17 2000-07-01 Univ Madrid Complutense USE OF VIP PEPTIDES AND PACAP IN THE TREATMENT OF ENDOTOXIC SHOCK IN MAMMALS.
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6541033B1 (en) * 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU3867400A (en) * 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1233811A2 (en) * 1999-11-12 2002-08-28 Leo Rubin Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
US6235264B1 (en) * 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6593394B1 (en) * 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2001060863A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
AU2000265051A1 (en) 2000-02-18 2001-08-27 Dabur Research Foundation Vasoactive intestinal peptide analogs
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
ATE424413T1 (en) * 2000-06-16 2009-03-15 Lilly Co Eli ANALOGUE OF GLUCAGONE-LIKE PEPTIDE-1
US20050158362A1 (en) 2000-06-23 2005-07-21 Wheatley Margaret A. Polymeric, fiber matrix delivery systems for bioactive compounds
EP1792915A3 (en) * 2000-11-28 2008-03-12 MondoBIOTECH Licensing Out AG Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
CN101712722A (en) * 2000-12-07 2010-05-26 伊莱利利公司 Glp-1 fusion proteins
JP2004521093A (en) * 2000-12-13 2004-07-15 イーライ・リリー・アンド・カンパニー Long-term treatment plan using glucagon-like insulin stimulating peptide
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
EP1432730A4 (en) * 2001-08-23 2006-10-11 Lilly Co Eli Glucagon-like peptide-1 analogs
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
JP4249025B2 (en) 2001-11-06 2009-04-02 千寿製薬株式会社 Therapeutic agent for diseases involving dry eye and dry eye
ES2425738T3 (en) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060241028A1 (en) 2002-06-10 2006-10-26 Dorian Bevec Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
ES2368565T3 (en) * 2002-11-27 2011-11-18 Ils Inc. PEPTIDES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME.
EP1633382A4 (en) * 2003-05-14 2009-08-05 Dow Corning CONJUGATES BASED ON ACTIVE AGENTS AND REPEATED SEQUENCE PROTEIN POLYMERS, METHODS OF MAKING SAME, AND APPLICATIONS THEREOF
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP2007513053A (en) 2003-07-14 2007-05-24 モンドバイオテック ラボラトリーズ アンシュタルト A substance called vasoactive intestinal peptide with biological activity for the treatment of interstitial lung infection
WO2005014030A1 (en) * 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
US7928059B2 (en) 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
US20050203009A1 (en) * 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
US7803764B2 (en) * 2004-03-29 2010-09-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
DE602005005476T2 (en) * 2004-05-21 2009-03-05 Eli Lilly And Co., Indianapolis SELECTIVE PEPTIDIC AGONISTS OF THE VPAC2 RECEPTOR
CA2573439C (en) * 2004-06-11 2014-12-09 Vectus Biosystems Limited Compositions and methods for treating myocardial fibrosis comprising vasoactive intestinal peptide
US20080261863A1 (en) * 2004-06-12 2008-10-23 Bayer Pharmaceuticals Corp Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
EP1781692A2 (en) * 2004-08-18 2007-05-09 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
AU2005294125A1 (en) * 2004-10-08 2006-04-20 Transition Therapeutics Inc. Vasoactive intestinal polypeptide pharmaceuticals
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
EP1896072A4 (en) 2005-06-24 2013-01-09 Univ Duke DIRECT DRUG DELIVERY SYSTEM USING THERMAL RESPONSE BIOPOLYMERS
AU2006306236B2 (en) * 2005-10-26 2011-12-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
ATE458000T1 (en) * 2005-11-18 2010-03-15 Dabur Pharma Ltd TARGETED FUSION PROTEINS FOR CANCER THERAPY
RU2466738C2 (en) * 2005-12-09 2012-11-20 Вектас Байосистемз Лимитед Vip fragments and methods for using them
EP1971355B1 (en) * 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8367626B2 (en) * 2006-05-12 2013-02-05 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
WO2008030968A2 (en) 2006-09-06 2008-03-13 Phase Bioscience, Inc. Fusion peptide therapeutic compositions
ES2373824T3 (en) 2007-05-21 2012-02-09 Res International Sarl PEPTIDES WITH IMPROVED PROPERTIES THAT HAVE THE BIOLOGICAL ACTIVITY OF THE VASOACTIVE INTESTINAL PEPTIDE (PIV) AND ITS USE FOR THE TREATMENT OF PULMONARY DISEASES.
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc Compositions and methods for modifying properties of biologically active polypeptides
EP2926825A1 (en) * 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
WO2010048564A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
CA2804755C (en) * 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
HUE047354T2 (en) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Deuterated derivatives of ivacaftor
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9605186B2 (en) 2012-09-19 2017-03-28 Exxonmobil Chemical Patents Inc. Adhesive compositions of ethylene-based and propylene-based polymers
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis

Also Published As

Publication number Publication date
US20110178017A1 (en) 2011-07-21
WO2011020091A1 (en) 2011-02-17
KR101943420B1 (en) 2019-04-17
AU2017279636B2 (en) 2019-09-12
AU2010282250B2 (en) 2015-11-12
MX339031B (en) 2016-05-05
AU2010282250A1 (en) 2012-04-05
HUE032703T2 (en) 2017-10-30
JP2016000751A (en) 2016-01-07
US9029505B2 (en) 2015-05-12
ES2624478T3 (en) 2017-07-14
KR20170085611A (en) 2017-07-24
MX2012001979A (en) 2012-06-25
PL3311828T3 (en) 2021-11-22
RU2589255C2 (en) 2016-07-10
JP5801807B2 (en) 2015-10-28
US20240091313A1 (en) 2024-03-21
RU2012109553A (en) 2013-09-20
ES2870914T3 (en) 2021-10-28
CN102596217B (en) 2014-07-02
CN102596217A (en) 2012-07-18
EP2464370B1 (en) 2017-03-29
HUE054744T2 (en) 2021-12-28
US20160220642A1 (en) 2016-08-04
PT2464370T (en) 2017-05-17
JP2013501818A (en) 2013-01-17
PL2464370T3 (en) 2017-08-31
US9700598B2 (en) 2017-07-11
SG10201407329RA (en) 2015-01-29
EP3311828B1 (en) 2021-04-07
AU2016200897A1 (en) 2016-03-03
KR101887009B1 (en) 2018-08-09
JP2017066157A (en) 2017-04-06
EP2464370A4 (en) 2013-03-27
IL218116A (en) 2017-06-29
AU2017279636A1 (en) 2018-01-18
DK2464370T3 (en) 2017-05-15
IL218116A0 (en) 2012-04-30
KR20120062777A (en) 2012-06-14
EP3311828A1 (en) 2018-04-25
MX366935B (en) 2019-07-31
JP6229038B2 (en) 2017-11-08
EP2464370A1 (en) 2012-06-20
US20180008677A1 (en) 2018-01-11
JP6069441B2 (en) 2017-02-01
DK3311828T3 (en) 2021-06-28
CA2804755C (en) 2018-06-05
CA2804755A1 (en) 2011-02-17
PT3311828T (en) 2021-05-05
BR112012003327A2 (en) 2017-06-06
AU2016200897B2 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
IN2012DN02120A (en)
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
TW200716646A (en) (S)-N-methylnaltrexone
MX2010004374A (en) Protein scaffolds.
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
PH12012500862B1 (en) Il-17a antagonists
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
TN2010000213A1 (en) Wise binding antibodies and epitopes
MY156315A (en) Anti-vegf antibodies
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
BR112013032717A2 (en) glucagon / glp-1 receptor coagonists
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX353233B (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof.
MX359639B (en) METHODS and COMPOSITIONS FOR USE IN CELLULAR THERAPIES.
NZ595361A (en) Chimeric factor h binding proteins (fhbp) and methods of use
MX2010005589A (en) Personal care composition.
TW200700064A (en) Novel compounds
MY160560A (en) Compositions and methods for treatment of kidney disorders
MX2012003951A (en) Pharmaceutical preparation comprising recombinant hcg.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2010000979A (en) Methods and compositions for treating autoimmune disease.
MX2011011623A (en) Toll-like receptor 3 antagonists.
SG10201805749QA (en) Substantially animal protein-free recombinant furin and methods for producing same
WO2007045019A3 (en) Polyoleosins